Eric Small, 2025-26 ASCO President, shared a post on LinkedIn:
“I have just participated in an excellent joint ASCO/SMeO symposium at the annual congress of the Mexican Society of Oncology.
Congratulations to Dr. Yanin Chávarri Guerra for organizing such an interesting program! Also to the two commentators: Dr. Erika Ruiz García, chair of the Education Committee of the ASCO 2026 Annual Congress, and Dr. Alejandro Noguez Ramos, who contextualized the results of the ATOMIC and MATTERHORN trials, both presented in the plenary session of the ASCO 2025 Congress, in the framework of settings with limited resources.
While the results of these trials are truly transformative (and plenary-worthy!), they may be out of reach for many patients in low- and middle-income countries, where an estimated 70% of the world’s new cancer cases will occur. Both commentators underscored the need for clinical trials investigating de-escalation strategies to expand access to these treatments.”
Read more posts featuring Eric Small on OncoDaily.